Oral amphetamine composition

A method of treating attention deficit-hyperactivity disorder (ADHD) in a subject in need thereof, the method comprising, administering to the subject an orally disintegrating pharmaceutical composition comprising;

• (a) taste-masked drug containing particles comprising:
• (i) drug-containing core particles comprising a therapeutically effective amount of racemic amphetamine, or a pharmaceutically acceptable salt or ester thereof and at least one excipient;
• (ii) a first taste-masking membrane comprising a water-insoluble polymer and excluding pharmaceutically acceptable gastrosoluble polymers, wherein the first taste-masking membrane is disposed directly on the drug-containing core particles;
• and
• (iii) a second taste-masking membrane comprising a water-insoluble polymer and a gastrosoluble polymer at a ratio ranging from about 95/5 to about 50/50 by wt., wherein the second taste-masking membrane is disposed directly on the first taste-masking membrane,
• wherein the water-insoluble polymer is each independently ethylcellulose, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, or a neutral acrylate-methacrylate copolymer;
• (b) a disintegrant;
• (c) a sugar alcohol or saccharide, or mixture thereof;
• and
• wherein if the orally disintegrating pharmaceutical composition comprises 30 mg of racemic amphetamine sulfate, after administration the orally disintegrating pharmaceutical composition provides one or more of the following:
• an AUCinf ranging from about 80% to about 125% of about 400-600 hr*ng/mL;
• a Cmax ranging from about 80% to about 125% of about 25-35 ng/mL;
• or
• a Tmax ranging from about 80% to about 125% of about 2-4 hrs.